Outset Medical, Inc. announced that General Counsel John Brottem will depart the company effective September 11, 2026, to pursue other professional opportunities. The filing states that his departure is not due to any dispute or disagreement with management. Outset Medical operates in the medical device industry, designing and manufacturing dialysis systems.

Outset Medical, Inc. reported second quarter 2026 financial results with net revenue of $31.6 million, a 1% increase year-over-year and a 14% sequential rise. Gross margin expanded to 42%, up more than 400 basis points from the prior-year period, while operating expenses remained stable at $29.0 million. The company reported a net loss of $18.0 million compared to $18.5 million in the same period last year and ended the quarter with $151 million in cash and equivalents. Outset Medical signed a three-year, $40 million agreement with HCA Healthcare to refresh its Tablo dialysis systems across the nation's largest health system. The company reiterated its 2026 revenue guidance of $125 million to $130 million. Outset Medical is a medical technology company that manufactures and services the Tablo Hemodialysis System for clinical use in hospitals and homes.

Outset Medical, Inc. entered into a Refresh Amendment to its existing Purchasing Agreement with HCA Management Services, L.P. on June 14, 2026. Under this amendment, HCA will purchase new Tablo Hemodialysis Systems from 2026 through 2028 for an aggregate net contract value of approximately $40 million. The agreement establishes a framework for console and consumables purchases to support future growth within HCA hospitals. The company is reiterating its 2026 financial guidance and intends to provide further details on the amendment's financial impact later this year. Outset Medical, Inc. is a medical device company specializing in hemodialysis systems.